JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Cogent Biosciences Inc

Geschlossen

12.08 -0.33

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.92

Max

12.13

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.1M

-72M

Angestellte

205

EBITDA

-1.2M

-74M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+62.72% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.1B

1.7B

Vorheriger Eröffnungskurs

12.41

Vorheriger Schlusskurs

12.08

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Juli 2025, 17:53 UTC

Wichtige Markttreiber

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25. Juli 2025, 15:58 UTC

Ergebnisse
Wichtige Markttreiber

Aon Shares Rise After 2Q Earnings Beat

25. Juli 2025, 15:08 UTC

Wichtige Markttreiber

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25. Juli 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25. Juli 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25. Juli 2025, 20:40 UTC

Ergebnisse

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25. Juli 2025, 20:10 UTC

Ergebnisse

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 19:56 UTC

Ergebnisse

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25. Juli 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25. Juli 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25. Juli 2025, 19:01 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

Sale Could Fetch Around $1B, Sources Say -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH in Talks to Sell Marc Jacobs -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25. Juli 2025, 17:38 UTC

Wichtige Markttreiber

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25. Juli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25. Juli 2025, 17:13 UTC

Ergebnisse

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25. Juli 2025, 16:46 UTC

Ergebnisse

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25. Juli 2025, 16:45 UTC

Ergebnisse

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25. Juli 2025, 16:27 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. Juli 2025, 16:02 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25. Juli 2025, 15:34 UTC

Ergebnisse

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25. Juli 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25. Juli 2025, 15:05 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25. Juli 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25. Juli 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25. Juli 2025, 14:36 UTC

Market Talk
Ergebnisse

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

62.72% Vorteil

12-Monats-Prognose

Durchschnitt 19.64 USD  62.72%

Hoch 29 USD

Tief 9 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

9

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Strong Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.